Article ID Journal Published Year Pages File Type
8707100 Oral Oncology 2018 13 Pages PDF
Abstract
These findings emphasize the historically bleak prognoses in patients with R/M HNSCC following PBT progression. Anti-PD-1 therapies, namely pembrolizumab and nivolumab, represent novel treatment options that may improve clinical outcomes.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Dentistry, Oral Surgery and Medicine
Preview
Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review
Authors
, , , ,